

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

FITC anti-mouse CD3

RRID:AB_312660

Type: Antibody

Proper Citation

BioLegend Cat# 100203, RRID:AB_312660

Antibody Information

URL: http://antibodyregistry.org/AB_312660

Proper Citation: BioLegend Cat# 100203, RRID:AB_312660

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_312660

Vendor: BioLegend

Catalog Number: 100203

Alternative Catalog Numbers: 100204

Record Creation Time: 20250819T211059+0000

Record Last Update: 20250819T220738+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse CD3.

No alerts have been found for FITC anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 79 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Allman A, et al. (2025) Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs. *Immunity*, 58(1), 143.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. *Cell reports*, 44(7), 115866.

Shen Y, et al. (2025) PLAGL2 promotes HCC progression by recruiting tumour-associated macrophages via CCL2/CCR2 signalling. *British journal of pharmacology*.

Imanishi I, et al. (2025) A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation. *Cell reports*, 44(8), 116114.

Zhang S, et al. (2025) p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma. *Cell reports*, 45(1), 116769.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Hsu AY, et al. (2025) Neutrophil-derived vesicles control complement activation to facilitate inflammation resolution. *Cell*, 188(6), 1623.

Chen Y, et al. (2025) Macrophage-derived CTSS drives the age-dependent disruption of the blood-CSF barrier. *Neuron*, 113(7), 1082.

Yang Z, et al. (2025) Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity. *Science advances*, 11(29), eadw0797.

Xiao ZX, et al. (2025) Single mutation tunes IRF4 function and mediates B cell character to ameliorate murine lupus. *iScience*, 28(11), 113884.

Albuayjan HHH, et al. (2025) Role of galectin-9 in the development of gestational diabetes mellitus. *Scientific reports*, 15(1), 18981.

Li P, et al. (2025) ROR γ t is crucial for gut homeostasis by regulating the expression of HB-EGF rather than IL-22 in activated ILC3s. *Cell reports*, 44(6), 115793.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Liu J, et al. (2025) Engineered probiotics platform for oral delivery of antibody as a high-compliance alternative for immune-mediated inflammatory diseases. *Cell reports. Medicine*, 102523.

Xie M, et al. (2024) Noninvasive neuromodulation protects against doxorubicin-induced cardiotoxicity and inhibits tumor growth. *iScience*, 27(3), 109163.

Pan Y, et al. (2024) Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement. *Cell reports. Medicine*, 5(6), 101590.

Lim S, et al. (2024) Derivation of functional thymic epithelial organoid lines from adult murine thymus. *Cell reports*, 43(4), 114019.

Li JJ, et al. (2024) Differentiation route determines the functional outputs of adult megakaryopoiesis. *Immunity*, 57(3), 478.

Rakhymzhan A, et al. (2024) Optimized intravital three-photon imaging of intact mouse tibia links plasma cell motility to functional states. *iScience*, 27(10), 110985.

Nasr S, et al. (2024) A computational pipeline for identifying gene targets and signalling pathways in cancer cells to improve lymphocyte infiltration and immune checkpoint therapy efficacy. *EBioMedicine*, 104, 105167.